市場調査レポート

商品コード

進行性家族性肝内胆汁うっ滞治療薬市場：薬剤タイプ、流通チャネル、エンドユーザー別- 世界予測2024-2030年

Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global Forecast 2024-2030

出版日: 2024年01月15日 | 発行: 360iResearch

| ページ情報: 英文 198 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF, Excel & Online Access - 1 Year (Single User License)

USD 4,749 744,453円

レポートPDF及びExcelを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Up to 5 User License)

USD 5,749 901,213円

レポートPDF及びExcelを5名まで共有ご利用頂けるライセンスです。ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Site License)

USD 6,749 1,057,973円

レポートPDF及びExcelを同一事業所（所在地）内のすべての方でご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Enterprise User License)

USD 8,749 1,371,493円

レポートPDF及びExcelを同一企業の全世界の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

ご注意事項 :

本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

進行性家族性肝内胆汁うっ滞治療薬市場規模は2023年に8,394万米ドルと推計され、2024年には8,635万米ドルに達し、CAGR 4.26%で2030年には1億1,243万米ドルに達すると予測されています。

進行性家族性肝内胆汁うっ滞治療薬の世界市場

主な市場の統計
基準年[2023］	8,394万米ドル
予測年[2024］	8,635万米ドル
予測年［2030]	1億1,243万米ドル
CAGR（%）	4.26%

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは進行性家族性肝内胆汁うっ滞治療薬市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、進行性家族性肝内胆汁うっ滞治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-進行性家族性肝内胆汁うっ滞治療薬市場の市場規模および予測は？

2-進行性家族性肝内胆汁うっ滞治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-進行性家族性肝内胆汁うっ滞治療薬市場における技術動向と規制の枠組みは？

4-進行性家族性肝内胆汁うっ滞治療薬市場における主要ベンダーの市場シェアは？

5-進行性家族性肝内胆汁うっ滞治療薬市場への参入に適した形態や戦略的手段は？

市場力学
- 促進要因
  - 高齢者人口と肝障害の増加
  - 進行性家族性肝内胆汁うっ滞（PFIC）2型治療のための新薬の研究開発の増加
  - 規制当局からの医薬品承認の増加
- 抑制要因
  - 高額な治療費と治療の失敗
- 機会
  - 部分的胆管ドレナージ（PIBD）の開発
  - PFICを治療するための新しいオデキシバット療法の開発
- 課題
  - 肝移植後のPFICの再発
市場セグメンテーション分析
市場動向分析
高インフレの累積的影響
ポーターのファイブフォース分析
バリューチェーンとクリティカルパス分析
規制の枠組み

第6章進行性家族性肝内胆汁うっ滞治療薬市場薬剤の種類別

コレスチラミン
リファンピシン
ウルソデオキシコール酸

第7章進行性家族性肝内胆汁うっ滞治療薬市場：流通チャネル別

病院薬局
オンライン薬局
小売薬局

第8章進行性家族性肝内胆汁うっ滞治療薬市場：エンドユーザー別

外来手術センター
病院
専門クリニック

第9章南北アメリカの進行性家族性肝内胆汁うっ滞治療薬市場

アルゼンチン
ブラジル
カナダ
メキシコ
米国

第10章アジア太平洋地域の進行性家族性肝内胆汁うっ滞治療薬市場

オーストラリア
中国
インド
インドネシア
日本
マレーシア
フィリピン
シンガポール
韓国
台湾
タイ
ベトナム

第11章欧州・中東・アフリカの進行性家族性肝内胆汁うっ滞治療薬市場

デンマーク
エジプト
フィンランド
フランス
ドイツ
イスラエル
イタリア
オランダ
ナイジェリア
ノルウェー
ポーランド
カタール
ロシア
サウジアラビア
南アフリカ
スペイン
スウェーデン
スイス
トルコ
アラブ首長国連邦
英国

第12章競合情勢

FPNVポジショニングマトリクス
市場シェア分析：主要企業別
競合シナリオ主要企業別の分析

第13章競争力のあるポートフォリオ

主要な企業プロファイル
- AbbVie, Inc.
- Akorn, Inc.
- Albireo Pharma, Inc.
- Glenmark Pharmaceuticals Limited
- Mirum Pharmaceuticals
- Novartis AG
- Par Pharmaceuticals, Inc.
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- Vivet Therapeutics
主要な製品ポートフォリオ

第14章付録

ディスカッションガイド
ライセンスと価格について

図表

LIST OF FIGURES

FIGURE 1. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET DYNAMICS
FIGURE 7. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 8. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 10. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 12. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

TABLE 1. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 6. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 10. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 14. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 21. ARGENTINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 24. BRAZIL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 27. CANADA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 28. CANADA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 29. CANADA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 30. MEXICO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 31. MEXICO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 32. MEXICO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 37. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. AUSTRALIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 44. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 45. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 47. INDIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 48. INDIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. INDIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 50. INDONESIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 53. JAPAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 54. JAPAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. JAPAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 56. MALAYSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 59. PHILIPPINES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 62. SINGAPORE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 65. SOUTH KOREA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 68. TAIWAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 71. THAILAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 72. THAILAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. THAILAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 74. VIETNAM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 81. DENMARK PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 82. DENMARK PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. DENMARK PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 84. EGYPT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 85. EGYPT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. EGYPT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 87. FINLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 88. FINLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. FINLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 90. FRANCE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 91. FRANCE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. FRANCE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 93. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 94. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 96. ISRAEL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 99. ITALY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 100. ITALY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. ITALY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 102. NETHERLANDS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 105. NIGERIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 108. NORWAY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 109. NORWAY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. NORWAY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 111. POLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 112. POLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. POLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 114. QATAR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 115. QATAR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. QATAR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 123. SOUTH AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 126. SPAIN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 127. SPAIN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. SPAIN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 129. SWEDEN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 132. SWITZERLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 135. TURKEY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 136. TURKEY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. TURKEY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 144. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 145. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 146. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET LICENSE & PRICING

Product Code: MRR-AD517FAAA612

[198 Pages Report] The Progressive Familial Intrahepatic Cholestasis Treatment Market size was estimated at USD 83.94 million in 2023 and expected to reach USD 86.35 million in 2024, at a CAGR 4.26% to reach USD 112.43 million by 2030.

Global Progressive Familial Intrahepatic Cholestasis Treatment Market

KEY MARKET STATISTICS
Base Year [2023]	USD 83.94 million
Estimated Year [2024]	USD 86.35 million
Forecast Year [2030]	USD 112.43 million
CAGR (%)	4.26%

Progressive Familial Intrahepatic Cholestasis Treatment Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Progressive Familial Intrahepatic Cholestasis Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Progressive Familial Intrahepatic Cholestasis Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Progressive Familial Intrahepatic Cholestasis Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Akorn, Inc., Albireo Pharma, Inc., Glenmark Pharmaceuticals Limited, Mirum Pharmaceuticals, Novartis AG, Par Pharmaceuticals, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Vivet Therapeutics.

Market Segmentation & Coverage

This research report categorizes the Progressive Familial Intrahepatic Cholestasis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Type
- Cholestyramine
- Rifampicin
- Ursodeoxycholic Acid
Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
End-Users
- Ambulatory Surgical Centers
- Hospitals
- Specialty Clinics
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Progressive Familial Intrahepatic Cholestasis Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Progressive Familial Intrahepatic Cholestasis Treatment Market?

3. What are the technology trends and regulatory frameworks in the Progressive Familial Intrahepatic Cholestasis Treatment Market?

4. What is the market share of the leading vendors in the Progressive Familial Intrahepatic Cholestasis Treatment Market?

5. Which modes and strategic moves are suitable for entering the Progressive Familial Intrahepatic Cholestasis Treatment Market?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rise in prevalence of geriatric population and liver disorder
  - 5.1.1.2. Rise in research and development of novel drugs for progressive familial intrahepatic cholestasis (PFIC) type 2 treatment
  - 5.1.1.3. Increase in drug approvals from regulatory bodies
- 5.1.2. Restraints
  - 5.1.2.1. High cost of treatments and failure of therapies
- 5.1.3. Opportunities
  - 5.1.3.1. Development of partial internal biliary drainages (PIBD)
  - 5.1.3.2. Development of novel odevixibat therapies to treat PFIC
- 5.1.4. Challenges
  - 5.1.4.1. Recurrence of PFIC Post liver transplantation
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Drug Type

6.1. Introduction
6.2. Cholestyramine
6.3. Rifampicin
6.4. Ursodeoxycholic Acid

7. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Distribution Channel

7.1. Introduction
7.2. Hospital Pharmacies
7.3. Online Pharmacies
7.4. Retail Pharmacies

8. Progressive Familial Intrahepatic Cholestasis Treatment Market, by End-Users

8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Hospitals
8.4. Specialty Clinics

9. Americas Progressive Familial Intrahepatic Cholestasis Treatment Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Progressive Familial Intrahepatic Cholestasis Treatment Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Progressive Familial Intrahepatic Cholestasis Treatment Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
- 13.1.1. AbbVie, Inc.
- 13.1.2. Akorn, Inc.
- 13.1.3. Albireo Pharma, Inc.
- 13.1.4. Glenmark Pharmaceuticals Limited
- 13.1.5. Mirum Pharmaceuticals
- 13.1.6. Novartis AG
- 13.1.7. Par Pharmaceuticals, Inc.
- 13.1.8. Sanofi S.A.
- 13.1.9. Teva Pharmaceutical Industries Ltd.
- 13.1.10. Viatris Inc.
- 13.1.11. Vivet Therapeutics
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

進行性家族性肝内胆汁うっ滞治療薬市場：薬剤タイプ、流通チャネル、エンドユーザー別- 世界予測2024-2030年

Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global Forecast 2024-2030

本レポートは、以下の側面に関する貴重な洞察を提供しています：

本レポートは、以下のような主要な質問に対応しています：

目次

第1章序文

第2章調査手法

第3章エグゼクティブサマリー

第4章市場の概要

第5章市場洞察

第6章進行性家族性肝内胆汁うっ滞治療薬市場薬剤の種類別

第7章進行性家族性肝内胆汁うっ滞治療薬市場：流通チャネル別

第8章進行性家族性肝内胆汁うっ滞治療薬市場：エンドユーザー別

第9章南北アメリカの進行性家族性肝内胆汁うっ滞治療薬市場

第10章アジア太平洋地域の進行性家族性肝内胆汁うっ滞治療薬市場

第11章欧州・中東・アフリカの進行性家族性肝内胆汁うっ滞治療薬市場

第12章競合情勢

第13章競争力のあるポートフォリオ

第14章付録

LIST OF FIGURES

LIST OF TABLES

This research report categorizes the Progressive Familial Intrahepatic Cholestasis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Drug Type

7. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Distribution Channel

8. Progressive Familial Intrahepatic Cholestasis Treatment Market, by End-Users

9. Americas Progressive Familial Intrahepatic Cholestasis Treatment Market

10. Asia-Pacific Progressive Familial Intrahepatic Cholestasis Treatment Market

11. Europe, Middle East & Africa Progressive Familial Intrahepatic Cholestasis Treatment Market

12. Competitive Landscape

13. Competitive Portfolio

14. Appendix

進行性家族性肝内胆汁うっ滞治療薬市場：薬剤タイプ、流通チャネル、エンドユーザー別- 世界予測2024-2030年

Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global Forecast 2024-2030

本レポートは、以下の側面に関する貴重な洞察を提供しています：

本レポートは、以下のような主要な質問に対応しています：

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

第6章 進行性家族性肝内胆汁うっ滞治療薬市場薬剤の種類別

第7章 進行性家族性肝内胆汁うっ滞治療薬市場：流通チャネル別

第8章 進行性家族性肝内胆汁うっ滞治療薬市場：エンドユーザー別

第9章 南北アメリカの進行性家族性肝内胆汁うっ滞治療薬市場

第10章 アジア太平洋地域の進行性家族性肝内胆汁うっ滞治療薬市場

第11章 欧州・中東・アフリカの進行性家族性肝内胆汁うっ滞治療薬市場

第12章 競合情勢

第13章 競争力のあるポートフォリオ

第14章 付録

LIST OF FIGURES

LIST OF TABLES

This research report categorizes the Progressive Familial Intrahepatic Cholestasis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Drug Type

7. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Distribution Channel

8. Progressive Familial Intrahepatic Cholestasis Treatment Market, by End-Users

9. Americas Progressive Familial Intrahepatic Cholestasis Treatment Market

10. Asia-Pacific Progressive Familial Intrahepatic Cholestasis Treatment Market

11. Europe, Middle East & Africa Progressive Familial Intrahepatic Cholestasis Treatment Market

12. Competitive Landscape

13. Competitive Portfolio

14. Appendix

第1章序文

第2章調査手法

第3章エグゼクティブサマリー

第4章市場の概要

第5章市場洞察

第6章進行性家族性肝内胆汁うっ滞治療薬市場薬剤の種類別

第7章進行性家族性肝内胆汁うっ滞治療薬市場：流通チャネル別

第8章進行性家族性肝内胆汁うっ滞治療薬市場：エンドユーザー別

第9章南北アメリカの進行性家族性肝内胆汁うっ滞治療薬市場

第10章アジア太平洋地域の進行性家族性肝内胆汁うっ滞治療薬市場

第11章欧州・中東・アフリカの進行性家族性肝内胆汁うっ滞治療薬市場

第12章競合情勢

第13章競争力のあるポートフォリオ

第14章付録